Entera Bio (ENTX) Cost of Revenue (2021 - 2025)

Entera Bio has disclosed Cost of Revenue across 4 years of filings, most recently posting $42000.0 for Q1 2025.

• Quarterly Cost of Revenue changed N/A year-over-year to $42000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $42000.0 (down 75.58% YoY) and the FY2025 annual result came in at $42000.0, down 75.58% from the prior year.
• Cost of Revenue slipped to $42000.0 in Q1 2025, from $82000.0 in the prior quarter.
• Over five years, Cost of Revenue peaked at $136000.0 in Q4 2021 and troughed at $6000.0 in Q3 2022.
• A 4-year average of $57333.3 and a median of $51000.0 in 2022 frame the typical range for Cost of Revenue.
• Biggest YoY gain for Cost of Revenue was 26.03% in 2022; the steepest drop was 94.12% in 2022.
• Tracing ENTX's Cost of Revenue over 4 years: stood at $136000.0 in 2021, then plunged by 94.12% to $8000.0 in 2022, then surged by 925.0% to $82000.0 in 2024, then sank by 48.78% to $42000.0 in 2025.
• Business Quant data shows ENTX's Cost of Revenue at $42000.0 in Q1 2025, $82000.0 in Q4 2024, and $42000.0 in Q3 2024.